 | 45% | Unknown (6873) |
 | 7% | Ukraine (1001) |
 | 6% | Russian Federation (915) |
 | 6% | Germany (861) |
 | 5% | France (778) |
 | 4% | United Kingdom (672) |
 | 4% | Netherlands (605) |
 | 3% | Italy (432) |
 | 3% | India (425) |
 | 1% | Switzerland (187) |
 | 1% | Poland (158) |
 | <1% | Spain (153) |
 | <1% | Macedonia, Former Yugoslav Republic (134) |
 | <1% | Brazil (114) |
 | <1% | Australia (110) |
 | <1% | Canada (100) |
 | <1% | China (93) |
 | <1% | Japan (83) |
 | <1% | Israel (72) |
 | <1% | Kenya (71) |
Welcome to the CML Advocates Network!
We are a worldwide network of non-profit organisations supporting patients with Chronic Myeloid Leukemia (CML) and their relatives. We do this by sharing knowledge and best practice, supporting campaigns, and educating advocates how to build and grow patient groups. The network is solely run by volunteers who are CML patients themselves.
This is what you can do here: Find CML patient groups in our worldwide directory of CML patient groups. Find out more about the CML Advocates Network. See our directory of web links. If you are representing a CML patient group, please log in to access our Wiki, our discussion forum, our photo gallery or our download area -- or please register if you are not yet a member.
 The "CML Advocates Network", an international platform for patient groups supporting patients and relatives suffering from "Chronic Myeloid Leukaemia" (CML) now connects 63 organisations from 50 countries across all continents. This worldwide network offers support by sharing of best practice, information and advice for CML patient representatives. We are delighted to welcome our newest members CML Life from Slovakia, AIL from Italy, CML-STOP from Russia, ASOPALEU from Guatemala and ALMA from Argentina!Read more...
Like every year in December, about 21.000 hematologists and health professionals (as well as a small group of patient advocates) convened at the Annual Meeting of the American Society of Hematology (ASH) to hear latest news from research in leukemias, lymphomas and other blood disorders. We have attended the scientific CML sessions at ASH 2011 and are now summarizing the most important presentations and posters, complemented by a patients' perspective. This report covers key presentations on Nilotinib, Dasatinib, Bosutinib, Ponatinib, DCC-2036, Imatinib-Interferon combination, STOP studies, as well as some studies on CML and diabetes or fatigue. (Translations: English - Russian - Hebrew - German - French - Macedonian) To improve the information available to patients, an international CML workgroup of patient organisations and experts have developed a patient-friendly summary of recommendations for CML management. The recommendations were published by CML experts on behalf of the European LeukemiaNet (ELN) in the Journal of Clinical Oncology in 2009. While treatment guidelines and recommendations are recognised as being the standard of care by haematologists, they can be difficult for patients to understand. Our summary, now available in 5 languages, aims to help patients to better understand CML management and communicate with their doctors regarding treatment and diagnostics.
The EORTC (European Organization for Research and Treatment of Cancer) "Quality of Life"Group, in collaboration with the GIMEMA (Italian Group Adult Hematologic Diseases), is coordinating a large international initiative whose main purpose is to develop an internationally validated questionnaire to assess the quality of life (QoL) of patients with chronic myeloid leukemia (CML). CML patients are being recruited in various hospitals in different countries to participate to this project, however, your contribution can further strength the quality of this project. The international scientific community believes that this research is very important because currently there is no "instrument" that allows doctors to know what are the most relevant health concerns for patients with CML. The research group is calling patient advocates to contribute to survey.
|
Traditionally, the first day of the ASH Congress features Education Sessions. These sessions provide hematologists with the overall picture on a specific disease, including its biology, standard of care, current therapeutic challenges, results from recent trials and future outlook. This year, Prof Neil Shah (USA), Andreas Hochhaus (Germany) and Junia Melo (Australia) presented the state of play in CML treatment and care. 
